ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 856,17
0,12%
DAX
18 726,76
-0,21%
Brent Oil
82,755
-0,93%
Bitcoin
69 808,21
-2,29%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. DMK Pharmaceuticals Corporation (DMK)

  7. DMK Pharmaceuticals Corporation (DMK) Actualités

DMK DMK Pharmaceuticals Corporation

0,232
0,00 (0,00%)
Dernière mise à jour : 02:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
DMK Pharmaceuticals Corporation DMK NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 0,232 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,232
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
21/3/202419:23EDGAR2Form 25-NSE - Notification filed by national security..
07/2/202423:19EDGAR2Form 8-K - Current report
06/2/202416:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202415:00EDGAR2Form 8-K - Current report
31/1/202423:17EDGAR2Form 8-K - Current report
23/1/202423:23EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/1/202423:22EDGAR2Form 8-K - Current report
03/1/202423:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03/1/202423:02EDGAR2Form 8-K - Current report
03/1/202423:00EDGAR2Form 8-K - Current report
21/12/202318:31EDGAR2Form 8-K - Current report
21/12/202314:15GLOBEDMK Pharmaceuticals Regains Full Rights to Commercialize..
04/12/202322:47EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/12/202322:45EDGAR2Form 8-K - Current report
28/11/202322:41EDGAR2Form 8-K - Current report
28/11/202314:05GLOBEDMK Pharmaceuticals Regains Full Rights from US WorldMeds..
15/11/202322:39EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/11/202322:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/11/202322:11EDGAR2Form 8-K - Current report
15/11/202322:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
14/11/202321:57EDGAR2Form 8-K - Current report
14/11/202313:30GLOBEDMK Pharmaceuticals Reports Third Quarter 2023 Financial..
13/11/202316:52GLOBEDMK Pharmaceuticals Announces Presentation of Preclinical..
02/11/202321:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:31EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/10/202312:30GLOBEDMK Pharmaceuticals Announces Inducement Option Grant Under..
25/10/202323:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/10/202323:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/10/202322:15GLOBEDMK Pharmaceuticals Announces Inducement Option Grant Under..
19/10/202323:07EDGAR2Form 8-K - Current report
19/10/202322:05GLOBEDMK Pharmaceuticals Restructures Executive Team to Support..
17/10/202322:37EDGAR2Form 8-K - Current report
17/10/202318:28EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
12/10/202322:22EDGAR2Form DEFC14A - Definitive proxy statement, contested..
10/10/202312:01EDGAR2Form 8-K - Current report
02/10/202322:49EDGAR2Form PREC14A - Preliminary proxy statements, contested..
26/9/202314:37EDGAR2Form SC 13D/A - General statement of acquisition of..
19/9/202323:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202318:00GLOBEAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals..

Dernières Valeurs Consultées

NASDAQ
DMK
DMK Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés